Biodistribution and Radiation Dosimetry for 68 Ga-DOTA-CCK-66, a Novel CCK 2 R-Targeting Compound for Imaging of Medullary Thyroid Cancer.

IF 9.6 3区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Clinical Nuclear Medicine Pub Date : 2024-12-01 Epub Date: 2024-08-02 DOI:10.1097/RLU.0000000000005355
Oliver Viering, Andreas Rinscheid, Nadine Holzleitner, Alexander Dierks, Malte Kircher, Georgine Wienand, Marianne Patt, Hans-Jürgen Wester, Ralph A Bundschuh, Thomas Günther, Constantin Lapa, Christian H Pfob
{"title":"Biodistribution and Radiation Dosimetry for 68 Ga-DOTA-CCK-66, a Novel CCK 2 R-Targeting Compound for Imaging of Medullary Thyroid Cancer.","authors":"Oliver Viering, Andreas Rinscheid, Nadine Holzleitner, Alexander Dierks, Malte Kircher, Georgine Wienand, Marianne Patt, Hans-Jürgen Wester, Ralph A Bundschuh, Thomas Günther, Constantin Lapa, Christian H Pfob","doi":"10.1097/RLU.0000000000005355","DOIUrl":null,"url":null,"abstract":"<p><strong>Abstract: </strong>Cholecystokinin 2 receptor (CCK 2 R) is a promising target for imaging and treatment of medullary thyroid cancer due to its overexpression in over 90% of tumor cells. 68 Ga-DOTA-CCK-66 is a recently introduced PET tracer selective for CCK 2 R, which has shown favorable pharmacokinetics in vivo in preclinical experiments. In order to further investigate safety and suitability of this tracer in the human setting, whole-body distribution and radiation dosimetry were evaluated.</p><p><strong>Patients and methods: </strong>Six patients with a history of medullary thyroid cancer were injected intravenously with 169 ± 19 MBq of 68 Ga-DOTA-CCK-66. Whole-body PET/CT scans were acquired at 10 minutes, 1 hour, 2 hours, and 4 hours after tracer injection. Time-activity curves per organ were determined, and mean organ-absorbed doses and effective doses were calculated using OLINDA/EXM.</p><p><strong>Results: </strong>Injection of a standard activity of 150 MBq of 68 Ga-DOTA-CCK-66 results in an effective dose of 4.5 ± 0.9 mSv. The highest absorbed organ doses were observed in the urinary bladder wall (40 mGy) and the stomach (15 mGy), followed by the kidneys (6 mGy), as well as the liver and the spleen (3 mGy each). CCK 2 R-expressing tumor manifestations could be detected in 2 of the 6 patients, including lymph node, bone, and liver metastases.</p><p><strong>Conclusions: </strong>68 Ga-DOTA-CCK-66 exhibits a favorable dosimetry. Beyond physiologic receptor expression of the stomach, no other relevant tracer accumulation could be observed, rendering this organ at risk in case of subsequent radioligand therapy using 177 Lu-DOTA-CCK-66.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":9.6000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Nuclear Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/RLU.0000000000005355","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/2 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

Abstract

Abstract: Cholecystokinin 2 receptor (CCK 2 R) is a promising target for imaging and treatment of medullary thyroid cancer due to its overexpression in over 90% of tumor cells. 68 Ga-DOTA-CCK-66 is a recently introduced PET tracer selective for CCK 2 R, which has shown favorable pharmacokinetics in vivo in preclinical experiments. In order to further investigate safety and suitability of this tracer in the human setting, whole-body distribution and radiation dosimetry were evaluated.

Patients and methods: Six patients with a history of medullary thyroid cancer were injected intravenously with 169 ± 19 MBq of 68 Ga-DOTA-CCK-66. Whole-body PET/CT scans were acquired at 10 minutes, 1 hour, 2 hours, and 4 hours after tracer injection. Time-activity curves per organ were determined, and mean organ-absorbed doses and effective doses were calculated using OLINDA/EXM.

Results: Injection of a standard activity of 150 MBq of 68 Ga-DOTA-CCK-66 results in an effective dose of 4.5 ± 0.9 mSv. The highest absorbed organ doses were observed in the urinary bladder wall (40 mGy) and the stomach (15 mGy), followed by the kidneys (6 mGy), as well as the liver and the spleen (3 mGy each). CCK 2 R-expressing tumor manifestations could be detected in 2 of the 6 patients, including lymph node, bone, and liver metastases.

Conclusions: 68 Ga-DOTA-CCK-66 exhibits a favorable dosimetry. Beyond physiologic receptor expression of the stomach, no other relevant tracer accumulation could be observed, rendering this organ at risk in case of subsequent radioligand therapy using 177 Lu-DOTA-CCK-66.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
用于甲状腺髓样癌成像的新型 CCK2R 靶向化合物 68Ga-DOTA-CCK-66 的生物分布和放射剂量测量法
摘要:由于胆囊收缩素2受体(CCK2R)在90%以上的肿瘤细胞中过表达,因此它是甲状腺髓样癌成像和治疗的一个很有前景的靶点。68Ga-DOTA-CCK-66是最近推出的对CCK2R具有选择性的PET示踪剂,在临床前实验中显示出良好的体内药代动力学。为了进一步研究这种示踪剂在人体环境中的安全性和适用性,我们对其全身分布和辐射剂量进行了评估:六名有甲状腺髓样癌病史的患者静脉注射了 169 ± 19 MBq 的 68Ga-DOTA-CCK-66。在注射示踪剂后 10 分钟、1 小时、2 小时和 4 小时分别进行全身 PET/CT 扫描。确定了每个器官的时间-活性曲线,并使用 OLINDA/EXM 计算了器官吸收的平均剂量和有效剂量:结果:注射标准活性为 150 MBq 的 68Ga-DOTA-CCK-66,有效剂量为 4.5 ± 0.9 mSv。吸收剂量最高的器官是膀胱壁(40 mGy)和胃(15 mGy),其次是肾脏(6 mGy)、肝脏和脾脏(各3 mGy)。6名患者中有2名可以检测到CCK2R表达的肿瘤表现,包括淋巴结、骨和肝转移:结论:68Ga-DOTA-CCK-66具有良好的剂量设计。结论:68Ga-DOTA-CCK-66表现出良好的放射剂量学特性,除了胃部的生理性受体表达外,未观察到其他相关的示踪剂累积,因此在随后使用177Lu-DOTA-CCK-66进行放射性配体治疗时,胃部器官将面临风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Clinical Nuclear Medicine
Clinical Nuclear Medicine 医学-核医学
CiteScore
2.90
自引率
31.10%
发文量
1113
审稿时长
2 months
期刊介绍: Clinical Nuclear Medicine is a comprehensive and current resource for professionals in the field of nuclear medicine. It caters to both generalists and specialists, offering valuable insights on how to effectively apply nuclear medicine techniques in various clinical scenarios. With a focus on timely dissemination of information, this journal covers the latest developments that impact all aspects of the specialty. Geared towards practitioners, Clinical Nuclear Medicine is the ultimate practice-oriented publication in the field of nuclear imaging. Its informative articles are complemented by numerous illustrations that demonstrate how physicians can seamlessly integrate the knowledge gained into their everyday practice.
期刊最新文献
68Ga-Prostate-Specific Membrane Antigen PET/CT in Endometrial Cancer: A Preliminary Report. 99mTc-PSMA and 99mTc-FAPI-46 Uptake in Pulmonary Lymphangitic Carcinomatosis: A Rare Form of Metastasis in Prostate Cancer Patient, Responding to Modified Treatments. FDG PET Images of Pseudoprogression After Nivolumab-FOLFOX Chemotherapy in a Gastric Cancer Patient. FDG PET/CT Image of Extragastrointestinal Stromal Tumor in the Posterior Mediastinum. Pictorial Essay: 18F FDG Brain PET-MR in Congenital Brain Anomalies Presenting With Seizures.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1